Our results were obtained by up-to-date biomarker assays and provide first comprehensive epidemiologic data for ongoing and upcoming clinical trials with MET/HGF inhibitors in soft tissue sarcomas and GIST. This evidence concerns the gene MET and gastrointestinal stromal tumor.